查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593905

淋巴瘤藥物市場：按治療方法、最終用戶分類 - 2025-2030 年全球預測

Lymphoma Therapeutics Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End User (Ambulatory Surgical Centers, Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年淋巴瘤治療市值為92.3億美元，預計2024年將達105億美元，複合年成長率為14.18%，預計2030年將達233.7億美元。

淋巴瘤藥物是指用於治療淋巴瘤（一種發生在淋巴系統中的癌症）並增加治癒機會的治療技術。這個市場包括化療和放射線治療等傳統治療方法，以及免疫療法、標靶治療和骨髓移植等先進方法。隨著全球淋巴瘤盛行率的不斷增加，對有效治療藥物的需求至關重要。這些治療方法適用於各種類型的淋巴瘤，包括何傑金氏病和非何傑金氏病，最終用戶包括醫院、專門的癌症治療中心和研究機構。市場成長主要受到淋巴瘤盛行率上升、生技藥品進步以及政府對癌症研究經費增加的影響。新藥療法的開發和核准也是一個重大機會。製藥公司正在積極投資研發，以發現 CAR T 細胞療法等創新療法，這些療法正在顯示出有希望的結果。然而，高昂的治療成本、嚴格的監管要求以及與當前治療方法相關的副作用等挑戰限制了市場的成長。為了利用不斷成長的機會，公司可以專注於個人化醫療和伴同性診斷，預計這將徹底改變淋巴瘤的治療。與學術機構合作進行突破性研究並透過策略夥伴關係關係擴大新興市場的進入可以進一步提高市場佔有率。市場競爭激烈，各大公司都在積極尋求提高其藥物的功效和安全性。對生物標的治療的投資以及在藥物發現中使用人工智慧被認為是創新的理想領域。此外，解決現有的挑戰（例如獲得治療和最佳化藥物輸送系統）可以提高競爭力並推動永續的業務成長。

主要市場統計
基準年[2023] 92.3億美元
預測年份 [2024] 105億美元
預測年份 [2030] 233.7億美元
複合年成長率（%） 14.18%

市場動態：快速發展的淋巴瘤藥物市場的關鍵市場洞察

供需的動態交互作用正在改變淋巴瘤藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 不同類型癌症的盛行率上升
    • 免疫查核點抑制劑和 Keytruda 等高級產品的採用率增加
    • 最近核准了多種新型療法
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 加強共同促銷和商業化
    • 擴大研發業務
  • 市場挑戰
    • 藥品專利到期

波特的五力戰略工具駕馭淋巴瘤藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解淋巴瘤藥物市場的外部影響

外部宏觀環境因素在塑造淋巴瘤治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解淋巴瘤治療藥物市場的競爭狀況

對淋巴瘤治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質淋巴瘤治療市場供應商的績效評估

FPNV定位矩陣是評估淋巴瘤治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃淋巴瘤治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對淋巴瘤治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 各種癌症的發生率上升
      • 免疫查核點抑制劑和 Keytruda 等高級產品的採用率增加
      • 最近核准了幾種新治療方法
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 擴大共同促銷和推銷
      • 研究和開發活動顯著成長
    • 任務
      • 藥品專利到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療分類的淋巴瘤藥物市場

  • 化療
  • 免疫療法
    • 嵌合體抗原受體T細胞療法
    • 免疫查核點抑制劑
    • 單株抗體
  • 放射治療
  • 幹細胞或骨髓移植
  • 外科手術
  • 標靶治療

第7章淋巴瘤治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 醫院

第8章美洲淋巴瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區淋巴瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲淋巴瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Accredo Health, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Seagen Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA326620

The Lymphoma Therapeutics Market was valued at USD 9.23 billion in 2023, expected to reach USD 10.50 billion in 2024, and is projected to grow at a CAGR of 14.18%, to USD 23.37 billion by 2030.

Lymphoma therapeutics refers to the treatment methodologies applied to manage and potentially cure lymphoma, which is a type of cancer that originates in the lymphatic system. The scope of this market includes not only conventional therapies such as chemotherapy and radiation but also advanced approaches like immunotherapy, targeted therapy, and bone marrow transplantation. With an increasing global incidence of lymphoma, the necessity of effective therapeutics is paramount. Applications of these therapies span across various types of lymphoma, including Hodgkin and Non-Hodgkin varieties, with end-users comprising hospitals, specialized cancer treatment centers, and research facilities. Market growth is primarily influenced by the rising prevalence of lymphoma, advancements in biologics, and increased government funding for cancer research. The development and approval of novel drug therapies also present significant opportunities. Pharmaceutical companies are actively investing in R&D to discover innovative treatments, such as CAR T-cell therapy, which have shown promising outcomes. However, challenges such as high treatment costs, stringent regulatory requirements, and adverse side effects associated with current therapies pose limitations to market growth. To leverage the growing opportunities, companies can focus on personalized medicine and companion diagnostics, which are predicted to revolutionize lymphoma treatment. Collaboration with academic institutions for breakthrough research and expanding access in emerging markets through strategic partnerships can further enhance market presence. The market's nature is highly competitive, with major players actively seeking advancement in drug efficacy and safety profiles. Investing in biologically targeted therapies and leveraging artificial intelligence for drug discovery are considered the best areas for innovation. Furthermore, addressing existing challenges such as treatment accessibility and optimizing drug delivery systems can provide a competitive edge and foster sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.23 billion
Estimated Year [2024] USD 10.50 billion
Forecast Year [2030] USD 23.37 billion
CAGR (%) 14.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lymphoma Therapeutics Market

The Lymphoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of different types of cancer
    • Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
    • Recent approval of several novel therapies
  • Market Restraints
    • High cost of therapies
  • Market Opportunities
    • Increasing co-promotion and commercialization
    • Extensive growth in R&D practices
  • Market Challenges
    • Patent expiry of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lymphoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lymphoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lymphoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lymphoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lymphoma Therapeutics Market

A detailed market share analysis in the Lymphoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lymphoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lymphoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lymphoma Therapeutics Market

A strategic analysis of the Lymphoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lymphoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Accredo Health, Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Lymphoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell or Bone Marrow Transplantation, Surgery, and Targeted Therapy. The Immunotherapy is further studied across Chimeric Antigen Receptor T-Cell Therapy, Immune Checkpoint Inhibitors, and Monoclonal Antibodies.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of different types of cancer
      • 5.1.1.2. Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
      • 5.1.1.3. Recent approval of several novel therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing co-promotion and commercialization
      • 5.1.3.2. Extensive growth in R&D practices
    • 5.1.4. Challenges
      • 5.1.4.1. Patent expiry of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lymphoma Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
    • 6.3.1. Chimeric Antigen Receptor T-Cell Therapy
    • 6.3.2. Immune Checkpoint Inhibitors
    • 6.3.3. Monoclonal Antibodies
  • 6.4. Radiation Therapy
  • 6.5. Stem Cell or Bone Marrow Transplantation
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Lymphoma Therapeutics Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Clinics
  • 7.4. Hospitals

8. Americas Lymphoma Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Lymphoma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Lymphoma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accredo Health, Inc.
  • 2. Amgen Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. Eli Lilly and Company
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Gilead Sciences, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Seagen Inc.
  • 13. Spectrum Pharmaceuticals, Inc.
  • 14. Takeda Pharmaceutical Company
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. LYMPHOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LYMPHOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LYMPHOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYMPHOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY STEM CELL OR BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023